Statement: the primary trial does not monitor the occurrence of Hemoglobin C Disease in its adverse events.
Primary_evidence: Adverse Events 1:   Total: 5/19 (26.32%)   Pain 3/19 (15.79%)   White blood cells (WBC) 5/19 (26.32%)   Hemoglobin (Hgb) 1/19 (5.26%)   Absolute neutrophil count (ANC) 5/19 (26.32%)   Platelets 3/19 (15.79%)   Elevated Aspartate Aminotransferase (AST) 1/19 (5.26%)   Elevated Alanine Aminotransferase (ALT) 1/19 (5.26%)   Dyspnea 3/19 (15.79%)